SCHEMBL18549331

SCHEMBL18549331

CCOC(=O)C(C(=O)OCC)=C(C)Nc1ccc(CC)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.49
SRC P12931 1/20 0.47
RAB9A P51151 6/20 0.47
NPC1 O15118 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
LMNA P02545 1/20 0.46
MAPK1 P28482 1/20 0.45
ALDH1A1 P00352 2/20 0.44
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
HDAC9 Q9UKV0 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18707907 0.85 CYP19A1 (0.54) MAPTRAB9ANPC1SMN1; SMN2MEN1
SCHEMBL8162593 0.82 MAPT (0.71) MAPTSRCRAB9ANPC1SMN1; SMN2
SCHEMBL21430760 0.81 POLB (0.58) MAPTSMN1; SMN2MEN1KMT2ALMNA
SCHEMBL4749285 0.80 HPGD (0.68) MAPTRAB9ANPC1SMN1; SMN2MEN1
SCHEMBL18550526 0.79 ALDH1A1 (0.42) MAPTRAB9ANPC1SMN1; SMN2KMT2A
SCHEMBL10205641 0.78 RAB9A (0.61) MAPTSRCRAB9ANPC1SMN1; SMN2
SCHEMBL2023219 0.75 SRC (0.63) SRCRAB9ANPC1SMN1; SMN2MEN1
SCHEMBL6391622 0.75 ALDH1A1 (0.58) MAPTRAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL8512504 0.74 GAA (0.54) MAPTRAB9ANPC1SMN1; SMN2MEN1
SCHEMBL9607477 0.74 GAA (0.54) MAPTRAB9ANPC1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022253283-A1 PROTEIN KINASE DEGRADANT AND USE THEREOF 中国科学院上海有机化学研究所 2022-12-08 WO disclosed
CN-108473434-B Substituted quinolone derivative or pharmaceutically acceptable salt or stereoisomer thereof, and medicinal composition and application thereof 上海海和药物研究开发股份有限公司 2021-11-23 CN disclosed
CN-113278010-A Protein kinase degradation agent and application thereof 中国科学院上海有机化学研究所 2021-08-20 CN disclosed
EP-3339294-B1 QUINOLONE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT, OR STEREOISOMER THEREOF AS AXL INHIBIOTOR SHANGHAI HAIHE PHARMACEUTICAL CO LTD (CN) 2021-04-14 EP disclosed
US-10683278-B2 Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) 2020-06-16 US disclosed
US-10683278-B2 Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) 2020-06-16 US disclosed
CN-106467541-B Substituted quinolone analog derivative or its pharmaceutically acceptable salt or stereoisomer and its Pharmaceutical composition and application 暨南大学 2019-04-05 CN disclosed
US-20180265496-A1 SUBSTITUTED QUINOLONE DERIVATIVES, OR PHARMACEUTICALLY ACCEPTABLE SALTS OR STEREOISOMERS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOF JINAN UNIVERSITY (CN) 2018-09-20 US disclosed
CN-108473434-A Substituted quinolone analog derivative or its pharmaceutically acceptable salt or stereoisomer and its Pharmaceutical composition and application 暨南大学 2018-08-31 CN disclosed
EP-3339294-A1 PHARMACEUTICAL COMPOSITION AND APPLICATION REPLACING QUINOLONE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT, OR STEREOISOMER Jinan University (CN) 2018-06-27 EP disclosed
CN-106467541-A Substituted quinolone analog derivative or its pharmaceutically acceptable salt or stereoisomer and its Pharmaceutical composition and application 暨南大学 2017-03-01 CN disclosed
WO-2017028797-A1 PHARMACEUTICAL COMPOSITION AND APPLICATION REPLACING QUINOLONE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT, OR STEREOISOMER 暨南大学 2017-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180265496-A1 SUBSTITUTED QUINOLONE DERIVATIVES, OR PHARMACEUTICALLY ACCEPTABLE SALTS OR STEREOISOMERS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOF NRAS, AXL, ABL1 MAPT 4122/4885SRC 7/4885RAB9A 757/4885
US-10683278-B2 Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof NRAS, AXL, ABL1 MAPT 4122/4885SRC 7/4885RAB9A 757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.